The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen.
 
Mara Rosenberg
No Relationships to Disclose
 
Guang Fan
No Relationships to Disclose
 
Kevin Watanabe-Smith
No Relationships to Disclose
 
Cristina Tognon
No Relationships to Disclose
 
Brian J. Druker
Stock and Other Ownership Interests - Aptose Biosciences; Beta Cat Pharmaceuticals; Blueprint Medicines; CTI; GRAIL; MolecularMD; Third Coast Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; ALLCRON, Inc; Aptose Biosciences; Baxalta; Beta Cat Pharmaceuticals; Blueprint Medicines; Celgene; Cepheid; CTI; Gilead Sciences; GRAIL; MolecularMD; Monojul, LLC; Roche TCRC; Third Coast Therapeutics
Research Funding - ARIAD (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Millipore via Dana-Farber Cancer Institute; Ohio State University
Travel, Accommodations, Expenses - Amgen; Amgen
 
Jeffrey Tyner
Consulting or Advisory Role - Leap Oncology
Research Funding - Aptose Biosciences; Array BioPharma; AstraZeneca/MedImmune; Constellation Pharmaceuticals; Genentech; Incyte; Janssen; Seagen; Takeda
 
Marc Loriaux
No Relationships to Disclose